ARTICLE | Clinical News
VB 1953: Ph I started
November 2, 2016 11:09 PM UTC
Vyome began an open-label, U.S. Phase I trial to evaluate topical VB 1953 applied twice daily for 14 days in about 14 patients....
BCIQ Company Profiles
Vyome began an open-label, U.S. Phase I trial to evaluate topical VB 1953 applied twice daily for 14 days in about 14 patients....
BCIQ Company Profiles